[go: up one dir, main page]

MX2017004213A - Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano. - Google Patents

Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano.

Info

Publication number
MX2017004213A
MX2017004213A MX2017004213A MX2017004213A MX2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A
Authority
MX
Mexico
Prior art keywords
dpr
dprs
derivatives
dipeptide
repetitions
Prior art date
Application number
MX2017004213A
Other languages
English (en)
Inventor
Montrasio Fabio
Grimm Jan
Original Assignee
Neurimmune Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding Ag filed Critical Neurimmune Holding Ag
Publication of MX2017004213A publication Critical patent/MX2017004213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proveen anticuerpos específicos de repetición de dipéptido (DPR) derivados de humano novedosos así como variantes sintéticas y derivados biotecnológicos de los mismos, de preferencia capaces de unirse a DPRs de C9ORF72, así como métodos relacionados con lo mismo. También se describen pruebas, kits, y soportes sólidos relacionados con anticuerpos específicos para DPRs y proteínas de DPR tales como C9ORF72-DPRs. El anticuerpo de la presente invención se puede utilizar en composiciones farmacéuticas y de diagnóstico para inmunoterapia dirigida a proteína de DPR y en productos de diagnóstico.
MX2017004213A 2014-09-30 2015-09-30 Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano. MX2017004213A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14187180 2014-09-30
EP15180310 2015-08-07
PCT/EP2015/072516 WO2016050822A2 (en) 2014-09-30 2015-09-30 Human-derived anti-dipeptide repeats (dprs) antibody

Publications (1)

Publication Number Publication Date
MX2017004213A true MX2017004213A (es) 2017-07-19

Family

ID=54238439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004213A MX2017004213A (es) 2014-09-30 2015-09-30 Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano.

Country Status (17)

Country Link
US (3) US10392447B2 (es)
EP (1) EP3201228A2 (es)
JP (5) JP6637971B2 (es)
KR (2) KR102594327B1 (es)
CN (1) CN108064248B (es)
AU (1) AU2021245147B2 (es)
BR (1) BR112017006598A2 (es)
CA (1) CA2960925A1 (es)
CO (1) CO2017002804A2 (es)
IL (2) IL278941B (es)
MX (1) MX2017004213A (es)
MY (1) MY180054A (es)
NZ (1) NZ729808A (es)
PH (1) PH12017500489A1 (es)
SG (2) SG11201701925XA (es)
WO (1) WO2016050822A2 (es)
ZA (2) ZA201701733B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHOD FOR MONITORING THE C9ORF72 EXPRESSION
RU2730677C2 (ru) 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
BR112016007751A2 (pt) 2013-10-11 2017-09-12 Ionis Pharmaceuticals Inc composições para modulação de expressão de c9orf72
CN108064248B (zh) 2014-09-30 2022-03-15 生物控股有限公司 人源抗二肽重复(dpr)抗体
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
BR112020021855A2 (pt) * 2018-04-27 2021-02-23 Biogen Ma Inc. anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
CN113164557A (zh) * 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
WO2020072428A1 (en) * 2018-10-01 2020-04-09 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
AU2019371814A1 (en) 2018-10-29 2021-06-17 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
WO2020107037A1 (en) * 2018-11-25 2020-05-28 President And Fellows Of Harvard College Compounds and methods for treating neurodegenerative diseases
EP3890752A1 (en) 2018-12-06 2021-10-13 Biogen MA Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
CN110470837B (zh) * 2019-08-30 2022-09-16 苏州西山生物技术有限公司 利用猴srv病毒gp20蛋白检测猴srv病毒的方法及其试剂盒
EP4034550A4 (en) * 2019-09-23 2023-09-27 University of Florida Research Foundation, Incorporated VACCINE THERAPY FOR RAN PROTEIN DISEASES
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
KR20250118954A (ko) 2024-01-31 2025-08-07 고등기술연구원연구조합 연속형 습식 co2 포집 시스템

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
FI895955A7 (fi) 1988-04-15 1989-12-13 Protein Design Labs Inc Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de) 1990-03-20 1997-10-15 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669986T3 (da) 1992-11-13 2003-07-28 Idec Pharma Corp Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
ATE352040T1 (de) 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
PL372140A1 (en) 2001-01-29 2005-07-11 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
WO2005018572A2 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2007222798A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2439490T3 (es) 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
US8709382B2 (en) * 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
JP5608091B2 (ja) * 2007-11-26 2014-10-15 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 抗メソセリン抗体およびその使用
US9133272B2 (en) * 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP6177231B2 (ja) * 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
US9783594B2 (en) * 2011-05-17 2017-10-10 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
CN106841594A (zh) * 2011-11-11 2017-06-13 美艾利尔圣地亚哥公司 检测杀白细胞的毒素（pvl）的装置和方法
PT2948777T (pt) 2013-01-22 2019-09-26 Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V Proteínas de repetição por dipeptídeos como alvo terapêutico em doenças neurodegenerativas com expansão de hexanucleotídico repetido
WO2014114303A1 (en) * 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
JP6628285B2 (ja) 2013-03-14 2020-01-08 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
CN108064248B (zh) 2014-09-30 2022-03-15 生物控股有限公司 人源抗二肽重复(dpr)抗体
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
SG11201701925XA (en) 2017-04-27
US20200010567A1 (en) 2020-01-09
WO2016050822A3 (en) 2016-06-02
KR102594327B1 (ko) 2023-10-27
AU2015326911A1 (en) 2017-03-30
US10961322B2 (en) 2021-03-30
MY180054A (en) 2020-11-20
CA2960925A1 (en) 2016-04-07
EP3201228A2 (en) 2017-08-09
JP2024102176A (ja) 2024-07-30
IL278941A (en) 2021-01-31
JP2020031660A (ja) 2020-03-05
JP6637971B2 (ja) 2020-01-29
AU2015326911B2 (en) 2021-07-08
BR112017006598A2 (en) 2018-04-17
CO2017002804A2 (es) 2017-06-20
SG10201902850TA (en) 2019-04-29
JP2021177788A (ja) 2021-11-18
WO2016050822A2 (en) 2016-04-07
US20240279361A1 (en) 2024-08-22
AU2021245147B2 (en) 2025-01-23
NZ729808A (en) 2022-02-25
US20170247471A1 (en) 2017-08-31
US10392447B2 (en) 2019-08-27
ZA201808270B (en) 2022-04-28
CN108064248A (zh) 2018-05-22
PH12017500489A1 (en) 2017-08-07
IL278941B (en) 2022-07-01
CN108064248B (zh) 2022-03-15
AU2021245147A1 (en) 2021-11-04
ZA201701733B (en) 2021-09-29
JP2024096261A (ja) 2024-07-12
IL251081A0 (en) 2017-04-30
KR20230104759A (ko) 2023-07-10
KR20170061702A (ko) 2017-06-05
JP2017538665A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
MX2017004213A (es) Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano.
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX389083B (es) Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet.
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
UY37463A (es) Proteínas de unión
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CO2019008675A2 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet
EP3186279C0 (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
UY38203A (es) Anticuerpo anti-repeticion de dipeptidos (dpr) de (poli-ga) derivado del ser humano
AR090923A1 (es) Anticuerpos anti-il-23
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
MX391037B (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
SMT202300125T1 (it) Proteina rep come antigene proteico per uso in saggi diagnostici
MX382055B (es) Nuevo anticuerpo igf - 1r y su uso para el diagnóstico del cáncer.
AR114843A1 (es) Anticuerpo anti-repetición de dipéptidos (dpr) de (poli-ga) derivado de ser humano
FR3028858B1 (fr) Anticorps monoclonal specifique de borrelia crocidurae et une methode de diagnostic in vitro d'une fievre recurrente de borreliose
EA202092790A1 (ru) Происходящее от человека антитело к дипептидным повторам (dpr)
HK1234426A1 (en) Human-derived anti-dipeptide repeats (dprs) antibody
TH1601003614A (th) การทดสอบวินิจฉัยโรคซึ่งถูกปรับปรุงสำหรับแอนทิบอดี csfv